Psilocybin does not reduce pain right away or over time in short- or long-term mouse pain models
Updated
Abstract
Psilocybin is not analgesic in mice across multiple pain models.
- The study evaluated psilocybin's effects on pain using various doses and pain assessments.
- No analgesic properties were observed for psilocybin in models of acute and chronic inflammatory pain.
- Psilocybin also did not show effectiveness in models of neuropathic or musculoskeletal pain.
- The findings challenge previous assumptions about psilocybin's potential therapeutic benefits for chronic pain.
Simplified
Funding
Competing interests
CONFLICT OF INTERESTS B.D.H. is on the scientific advisory boards of Journey Clinical and Osmind, and is a paid consultant to Arcadia Medicine, Inc, Tactogen, LLC, and Vida Ventures, LLC. R.C.M. is now on leave from Stanford, functioning as Chief Scientific Officer at Bayshore Global Management. R.C.M. is on the scientific advisory boards of MapLight Therapeutics, Bright Minds, MindMed, and Aelis Farma.
PubMed